MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation

Z. Mao, J. Xiong, Z. Min, Z. Xue (Wuhan, China)

Meeting: 2022 International Congress

Abstract Number: 1549

Keywords: 1-Methyl-4-phenylpyridinium (MPP+), Inflammation, Parkinson’s

Category: Parkinson's Disease: Pathophysiology

Objective: To explore the role and related mechanism of gut microbiota metabolites short-chain fatty acids(SCFAs) in the pathogenesis of Parkinson’s disease(PD).

Background: Growing research have shown that gut microbiota disturbance is involved in the pathogenesis of Parkinson’s disease, and its metabolites SCFAs may play an important role in it by triggering neuroinflammation. NLRP3 inflammasomes activation can induce PD by releasing inflammatory factors and inducing abnormal aggregation of a-synuclein(aSyn).

Method: 1) Mouse enteroendocrine cells STC-1 were treated with SCFAs, and the aSyn, phosphorylated aSyn(p-aSyn) expression levels were detected.
2) SH-SY5Y cells were cultured with the supernatant of SCFAs-treated STC-1, then transfected with NLRP3 siRNA or GPR43 siRNA, successively, and then we detected apoptosis, apoptosis-related proteins and tyrosine hydroxylase(TH), aSyn(p-aSyn), GPR43, NLRP3 inflammasomes expression.
3) C57BL/6 mice were administered MPTP twice per week for 5 weeks via intraperitoneal injection, fed with water containing SCFAs, then treated with NLRP3 inhibitor (CY-09) or GPR43 inhibitor (GLPG0974), successively, and then the motor function, defecation rate, fecal water content, aSyn(p-aSyn), TH, GPR43 and NLRP3 inflammasomes in the midbrain and ileum were detected.

Results: 1) SCFAs can increase aSyn expression in STC-1, and their supernatant can induce SH-SY5Y apoptosis, increase the expression of apoptosis-related proteins, p-aSyn, GPR43, NLRP3 inflammasomes, reduce TH expression.
2) NLRP3 siRNA and GPR43 siRNA can reduce the apoptosis, the expression of apoptosis-related proteins, p-aSyn, increase TH expression in SH-SY5Y cultured by SCFAs-treated STC-1 supernatant, and GPR43 siRNA can reduce NLRP3 inflammasomes expression.
3) SCFAs can induce dyskinesia in MPTP-treated mice, reduce defecation rate, fecal water content, increase aSyn deposition, the expression of GPR43 and NLRP3 inflammasome, reduce TH expression in midbrain and ileum. CY-09 and GLPG0974 can alleviate the dyskinesia of PD, increase the defecation rate, fecal water content,reduce aSyn deposition, increase TH expression in midbrain and ileum, and GLPG0974 can reduce NLRP3 inflammasomes expression.

Conclusion: SCFAs participate in the pathogenesis of PD by regulating NLRP3 inflammasomes activation through GPR43.

To cite this abstract in AMA style:

Z. Mao, J. Xiong, Z. Min, Z. Xue. SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/scfas-participate-in-the-pathogenesis-of-parkinsons-disease-by-regulating-nlrp3-inflammasomes-activation/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/scfas-participate-in-the-pathogenesis-of-parkinsons-disease-by-regulating-nlrp3-inflammasomes-activation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley